What is the 13F Pro Quality Score for OSUR?

13F Pro ranks ORASURE TECHNOLOGIES INC (OSUR) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View OSUR's current score at https://13fpro.ai/research/OSUR (free sign-up required for the full ranking).

Which hedge funds own the most OSUR stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of OSUR include BlackRock,, PRIVATE MANAGEMENT GROUP, Neuberger Berman Group. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/OSUR as soon as new 13F filings post.

Where does 13F Pro source OSUR data?

All ORASURE TECHNOLOGIES INC fundamentals and ownership data come directly from SEC EDGAR. ORASURE TECHNOLOGIES INC files with the SEC under CIK 1116463. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is OSUR in?

ORASURE TECHNOLOGIES INC (OSUR) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is OSUR research updated on 13F Pro?

OSUR's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ORASURE TECHNOLOGIES INC(OSUR)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1116463 OSUR stock profile & AI dashboard →

13F Pro Quality Score

11.5/100

Rank #2,792 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

2.0/100

Profitability

9.0/100

Balance Sheet

12.6/100

Earnings Quality

30.0/100

Free Cash Flow

9.4/100

Institutional Flow

14.5/100

Revenue Scale

19.0/100

Dilution Risk

18.5/100

OSUR Stock Analysis & AI Quality Score

AI stock analysis and institutional research for ORASURE TECHNOLOGIES INC (OSUR), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores OSUR at 11.5/100 on a 32-signal composite quality model, placing it at rank #2,792 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (2.0) and profitability (9.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 18.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), ORASURE TECHNOLOGIES INC reports quarterly revenue of $27.9M, net income of $-22.4M, free cash flow of $-14.8M. Top institutional holders of OSUR by reported 13-F value include BlackRock,, PRIVATE MANAGEMENT GROUP, Neuberger Berman Group, based on the most recent SEC filings. OSUR trades on the Nasdaq exchange and files with the SEC under CIK 1116463. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate OSUR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ORASURE TECHNOLOGIES INC directly from SEC EDGAR. ORASURE TECHNOLOGIES INC's 13F Pro composite quality score has ranged between 8 and 70 since 2021, currently 11.5 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about ORASURE TECHNOLOGIES INC

Quirks, history, and lore behind OSUR — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · listed on Nasdaq · headquartered in Pennsylvania · focused on diagnostics and specimen collection.
2
The Numbers
Annual revenue in the range of a few hundred million dollars, with sales historically spiking during public health crises when demand for rapid testing surges.
3
The History
Founded in the late 1980s, the company built its early reputation around oral fluid diagnostics — a novel idea at a time when blood was the default.
4
The Secret
It pioneered an FDA-approved HIV test that uses a swab from your mouth instead of a needle — no blood, no lab, results in about 20 minutes.
5
The Lore
When COVID-19 hit, this small-cap company became a household name in public health circles almost overnight, supplying rapid antigen tests to governments and clinics worldwide.
6
The Giveaway
Its flagship consumer HIV test — sold at pharmacies as OraQuick — is the only at-home oral HIV test the FDA has ever approved. Spit, wait, know.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$27.9M

Net Income

Q1 2026

$-22.4M

Free Cash Flow

Q1 2026

$-14.8M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-71.6% YoY

$115.0MFY 2025

FY20 $171.7MFY21 $233.7MFY23 $405.5MFY25 $115.0M

Net Income

-228.1% YoY

$-68.7MFY 2025

FY20 $-14.9MFY21 $-23.0MFY23 $53.7MFY25 $-68.7M

Operating Income

-320.2% YoY

$-72.0MFY 2025

FY20 $-5.2MFY21 $-10.2MFY23 $32.7MFY25 $-72.0M

EPS (Diluted)

-230.6% YoY

$-0.94FY 2025

FY20 $0.22FY21 $-0.32FY23 $0.72FY25 $-0.94

Total Assets

-16.5% YoY

$403.2MFY 2025

FY20 $454.5MFY21 $461.0MFY23 $482.8MFY25 $403.2M

Op. Cash Flow

-134.6% YoY

$-49.0MFY 2025

FY20 $5.8MFY21 $-35.4MFY23 $141.6MFY25 $-49.0M

Metric	FY 2025	FY 2023	FY 2021	FY 2020	FY 2018	FY 2016
Revenue	$115.0M -71.6%	$405.5M +73.5%	$233.7M +36.1%	$171.7M -5.5%	$181.7M +41.8%	$128.2M
Net Income	$-68.7M -228.1%	$53.7M +333.3%	$-23.0M -54.1%	$-14.9M -173.2%	$20.4M +3.4%	$19.7M
Operating Income	$-72.0M -320.2%	$32.7M +421.6%	$-10.2M -96.3%	$-5.2M -118.2%	$28.4M +40.3%	$20.3M
EPS (Diluted)	$-0.94 -230.6%	$0.72 +325.0%	$-0.32 -245.5%	$0.22 -33.3%	$0.33 -5.7%	$0.35
Total Assets	$403.2M -16.5%	$482.8M +4.7%	$461.0M +1.4%	$454.5M +44.0%	$315.6M +51.8%	$207.9M
Operating Cash Flow	$-49.0M -134.6%	$141.6M +500.2%	$-35.4M -709.3%	$5.8M -85.1%	$39.1M +58.9%	$24.6M

AI Insight: OSUR Financial Trends

Revenue has nearly halved from $54M in Q2 2024 to $28M in Q1 2026 while operating losses deepened to $23M, putting equity in a sustained decline.

• Revenue collapsed 48% from $54M in Q2 2024 to $28M in Q1 2026, with no quarter showing sequential recovery.

• Operating losses widened from $3M in Q2 2024 to $23M in Q1 2026, reflecting accelerating cash burn relative to revenue.

• Operating cash flow turned sharply negative, falling from $13M in Q3 2024 to -$14M in Q1 2026 — six consecutive quarters of deterioration.

• Equity has eroded steadily from $426M in Q2 2024 to $313M in Q1 2026, down $113M over eight quarters.

⚠ No debt is reported, but equity runway is shrinking fast; sustained -$14M quarterly operating cash flow raises near-term liquidity concerns.

⚠ Net loss widened to $22M in Q1 2026 — the largest single-quarter loss in the dataset — despite flat sequential revenue.

⚠ Revenue stabilization near $27–$28M for three consecutive quarters could signal a floor, but losses have not compressed alongside it.

AI Insight: OSUR Ratio Trends

OSUR's operating margin collapsed to -83.3% in Q1 2026, accelerating a deterioration that began at -5.0% just seven quarters ago.

• Operating margin deteriorated sharply from -5.0% in Q2 2024 to -83.3% in Q1 2026 — a 78pp collapse over seven quarters.

• ROA worsened from -0.5% in Q2 2024 to -23.6% in Q1 2026, signaling deeply negative asset productivity.

• ROIC fell from -2.6% in Q2 2024 to -29.7% in Q1 2026, reflecting accelerating capital destruction.

⚠ Q4 2025 and Q1 2026 operating margins of -75.1% and -83.3% suggest losses are intensifying, not stabilizing.

⚠ D/E data is absent across all periods — leverage visibility is zero, masking true balance sheet risk.

Get alerted when OSUR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ORASURE TECHNOLOGIES INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of OSUR

BlackRock, Inc.
$19.5M6,516,216 sh
PRIVATE MANAGEMENT GROUP INC
$16.3M5,422,129 sh
Neuberger Berman Group LLC
$13.1M4,361,901 sh
VANGUARD CAPITAL MANAGEMENT LLC
$9.1M3,030,888 sh
DIMENSIONAL FUND ADVISORS LP
$8.5M2,820,830 sh
SYSTEMATIC FINANCIAL MANAGEMENT LP
$7.4M2,480,483 sh
RENAISSANCE TECHNOLOGIES LLC
$6.2M2,083,303 sh
CANNELL CAPITAL LLC
$6.0M2,003,271 sh
GEODE CAPITAL MANAGEMENT, LLC
$5.5M1,820,019 sh
GAGNON SECURITIES LLC
$5.1M1,714,391 sh

Fund	Value	Shares
BlackRock, Inc.	$19.5M	6,516,216
PRIVATE MANAGEMENT GROUP INC	$16.3M	5,422,129
Neuberger Berman Group LLC	$13.1M	4,361,901
VANGUARD CAPITAL MANAGEMENT LLC	$9.1M	3,030,888
DIMENSIONAL FUND ADVISORS LP	$8.5M	2,820,830
SYSTEMATIC FINANCIAL MANAGEMENT LP	$7.4M	2,480,483
RENAISSANCE TECHNOLOGIES LLC	$6.2M	2,083,303
CANNELL CAPITAL LLC	$6.0M	2,003,271
GEODE CAPITAL MANAGEMENT, LLC	$5.5M	1,820,019
GAGNON SECURITIES LLC	$5.1M	1,714,391

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put OSUR on your watchlist

Track score changes the day ORASURE TECHNOLOGIES INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is OSUR a good stock to buy?

13F Pro's AI-powered analysis of ORASURE TECHNOLOGIES INC (OSUR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for OSUR are available on the OSUR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own OSUR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling OSUR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ORASURE TECHNOLOGIES INC's investment landscape.